Skip to main content
Clinical Trials/NCT04829045
NCT04829045
Completed
Not Applicable

The Effect of Acupuncture as Adjunctive Therapy on Homeostasis Model Assessment-insulin Resistance and Health Related Quality of Life in Patients With Type 2 Diabetes Mellitus

Universiti Putra Malaysia1 site in 1 country46 target enrollmentMay 27, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus, Type 2
Sponsor
Universiti Putra Malaysia
Enrollment
46
Locations
1
Primary Endpoint
Fasting serum insulin
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This study aims to determine the effect of acupuncture as an adjunctive therapy on homeostasis model assessment-insulin resistance (HOMA-IR) and health-related quality of life (HRQoL) in patients with type 2 diabetes mellitus.

Detailed Description

This is a randomised, double-blind, placebo controlled and parallel design trial. Participants will be randomized to either acupuncture (n=30) or placebo (n=30) using a 1:1 ratio. The permuted blocks with a block size of 2 will be used. Both groups will continue with their routine diabetes care. Primary outcome of HOMA-IR will be measured at the time of recruitment (baseline) and after completion of 10 sessions (week 7) of the treatment. Secondary outcome of HRQOL will be measured at the time of recruitment (baseline), after completion of 5 sessions (week 3/4) and 10 sessions (week 7) of the treatment while outcomes of body mass index and waist circumference are measured at the time of recruitment (baseline) and after completion of 10 sessions (week 7) of the treatment. Any adverse event will be recorded at every visit. The sequence generation and allocation will remain concealed from the patient and practitioner.

Registry
clinicaltrials.gov
Start Date
May 27, 2021
End Date
December 31, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Cheok Yean Chin

Principle Investigator

Universiti Putra Malaysia

Eligibility Criteria

Inclusion Criteria

  • Fasting plasma glucose (FPG) ≥ 7.0 mmol/L \[126 mg/dL\] or HbA1c ≥ 6.5%.
  • Subjects have had type 2 diabetes mellitus for more than one year
  • Receive oral anti-diabetic agents on a stable dose over the previous 3 months.

Exclusion Criteria

  • Under insulin therapy
  • With other acute or chronic health problems
  • Body mass index (BMI) ≥ 40.0 kg/m²
  • Needle phobia or allergy to adhesive plaster
  • Planning to move out from Malaysia within 4 months'
  • Being pregnant, planning for pregnancy or lactating women

Outcomes

Primary Outcomes

Fasting serum insulin

Time Frame: change from baseline fasting serum insulin at 7 weeks

Analyzed in μU/ml using heparin tube

Fasting plasma glucose

Time Frame: change from baseline fasting plasma glucose at 7 weeks

Analyzed in mmol l-\^1 using sodium fluoride tube

Homeostasis model assessment- insulin resistance (HOMA-IR)

Time Frame: change from baseline HOMA-IR at 7 weeks

Fasting serum insulin and fasting plasma glucose will be combined to report HOMA-IR in unit \[fasting serum insulin (μU/ml)×fasting plasma glucose (mmol l-1)/22.5\](Mathews et al., 1985).

Secondary Outcomes

  • Body mass index(change from baseline body mass index at 7 weeks)
  • Health-related quality of life (HRQoL)(change from baseline HRQoL at 7 weeks)
  • Weight(change from baseline weight at 7 weeks)
  • Waist circumference(change from baseline waist circumference at 7 weeks)
  • Incident of treatment adverse events in terms of intensity (grades 1 - 5)(7 weeks)

Study Sites (1)

Loading locations...

Similar Trials